16 material Form 8-K filings that 14 companies we cover made with the SEC in June 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Graco said its President of the Electric Motor Division and a named executive officer, Jeffrey P. Johnson, told the company on June 16, 2023 that he intends to retire effective December 31, 2023. The filing does not name a successor or describe any change to his compensation.
Jeffrey P. Johnson, President, Electric Motor Division, informed Graco of his retirement intention on June 16, 2023.
Retirement is effective December 31, 2023.
The filing does not name a successor or describe compensation changes.
Effective immediately, David Hammer and Kyle Christine are primarily responsible for the day-to-day management of PIMCO California Municipal Income Fund (PCQ). The filing describes their backgrounds, including Hammer's prior roles at PIMCO and Morgan Stanley and Christine's time at Morgan Stanley before joining PIMCO in 2017.
Effective immediately, Hammer and Christine are primarily responsible for day-to-day management of the fund
David Hammer is a Managing Director and municipal bond portfolio manager in the Newport Beach office; he rejoined PIMCO in 2015
Kyle Christine is a Senior Vice President and municipal bond portfolio manager in the Newport Beach office; he joined PIMCO in 2017
Chemomab Therapeutics appointed Sigal Fattal, its former VP of Finance, as Chief Financial Officer on June 1, 2023, and the Board approved her compensation on June 14, 2023. The package includes a $260,000 base salary, a bonus potential of 45% of base salary tied to objectives yet to be set, and options on 102,860 ADSs at $1.70 that vest over four years.
Appointed Sigal Fattal as Chief Financial Officer on June 1, 2023; she previously served as VP of Finance
Annual base salary of $260,000, plus a bonus potential of 45% of base salary
Options to buy 102,860 American Depositary Shares at $1.70, vesting over four years, with acceleration on a change in control
Chemomab Therapeutics replaced CEO Dale Pfost and CFO Donald Marvin effective June 1, 2023, reappointing co-founder Adi Mor as CEO and Sigal Fattal as CFO, and named Nissim Darvish Chairman. The company also said it is implementing further cost-reduction measures to extend its cash runway to the end of 2024 and is suspending initiation of a Phase 2 systemic sclerosis trial to preserve capital.
Adi Mor appointed CEO effective June 1, 2023; her compensation will be set later and subject to shareholder approval
Sigal Fattal appointed CFO, replacing Donald Marvin, effective June 1, 2023
Cash runway expected to extend from mid-year 2024 to end of 2024, after the Phase 2 PSC topline data readout expected in the latter part of 2024
Former CEO Dale Pfost will receive 12 months of base salary in cash, accelerated stock option vesting and 12 months of COBRA premiums, subject to a separation agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.